We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Zika Virus IgM Antibody Found in West Nile Virus Patients

By LabMedica International staff writers
Posted on 18 Aug 2021
Print article
Image: The Zika IgM antibody-capture, enzyme-linked immunosorbent assay (Zika MAC-ELISA) for antibody testing (Photo courtesy of the Centers for Diseases Control and Prevention).
Image: The Zika IgM antibody-capture, enzyme-linked immunosorbent assay (Zika MAC-ELISA) for antibody testing (Photo courtesy of the Centers for Diseases Control and Prevention).
West Nile virus (WNV) and Zika virus (ZIKV) are mosquito-borne viruses in the family Flaviviridae. Residents in, and travelers to, areas where the viruses are circulating are at risk for infection, and both viruses can cause an acute febrile illness.

In the contiguous USA, WNV disease is the most commonly reported arboviral disease, with about 2,000 to 6,000 reported cases each year. WNV disease presentations range from mild febrile illness to severe neuroinvasive disease. Almost all ZIKV disease cases in the continental USA are travel associated.

Vector Borne Disease experts at the Centers for Diseases Control and Prevention (CDC, Fort Collins, CO, USA) included serum samples from 153 persons with confirmed recent WNV infection in their analysis. The median age of patients was 59 years (range 10–92 years) and 53 (35%) were female. Samples were collected at a median of seven days (range 0–40 days) after symptom onset. Serum samples were tested for the presence of ZIKV IgM antibody with CDC's envelope protein antigen-based ZIKV IgM antibody capture-ELISA (Zika MAC-ELISA). A P/N value <2.0 was interpreted as negative, a P/N from 2.0 to <3.0 was equivocal, and a P/N ≥ 3.0 was positive.

The scientists reported that among 153 sera from patients with acute WNV infection, the ZIKV IgM antibody result was positive in 56 (37%; 95% confidence interval [CI] 29–44%) and equivocal in 28 (18%; 95% CI 13–25%). With 55% of samples having cross-reactive antibodies, it is important for health care providers to request appropriate testing based on the most likely cause of a patient's possible arboviral infection considering their clinical symptoms and signs, travel history, and place of residence. Patients were significantly more likely to have a ZIKV IgM antibody-positive or equivocal result if their sample had both WNV and St. Louis encephalitis virus (SLEV)-neutralizing antibodies, compared with patients with samples with only WNV-neutralizing antibodies (relative risk = 2.1), and this association was not modified by nor required adjustment for sex.

The authors concluded that for cases where the epidemiology does not support the preliminary IgM findings, confirmatory neutralizing antibody testing should be performed. These measures will avoid an incorrect diagnosis of ZIKV infection, based on cross-reactive antibodies, in a person truly infected with WNV. The study was published on July 22, 2021 in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Centers for Diseases Control and Prevention

Gold Supplier
Automated RNA Extraction & PCR Setup
Omnia LH 75 Pro
Silver Supplier
COVID-19 IgG-IgM Rapid Test
COVID-19 IgG-IgM Rapid Test
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.